Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
BACKGROUND
Bruton's tyrosine kinase (BTK) has emerged as a new anti-apoptotic molecular target for the treatment of B-lineage leukemias and lymphomas. Preclinical and early clinical results indicate that BTK inhibitors may be useful in the treatment of leukemias and lymphomas. BTK inhibitors may also be helpful in prevention and treatment of thromboembolic complications as well as inflammatory disorders.


METHODS
We provide a comprehensive review of the target diseases for which the use of BTK inhibitors may be helpful as well as the activity profiles of BTK inhibitors.


RESULTS
We review the currently available translational research, biomarker as well as patent literature regarding BTK molecular target and BTK inhibitors.


CONCLUSIONS
BTK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias/lymphomas, inflammatory disorders and autoimmunity.
Uckun
Fatih M
FM
University of Southern California Keck School of Medicine, Children's Center for Cancer and Blood Diseases, Division of Hematology-Oncology, Department of Pediatrics, Los Angeles, CA 90027-0367, USA. fmuckun@chla.usc.edu
Qazi
Sanjive
S
D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D007938:Leukemia / Q000188:drug therapy / Q000503:physiopathology; D008223:Lymphoma / Q000188:drug therapy / Q000503:physiopathology; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human